Trial record 15 of 17 for:    Open Studies | "Tuberous Sclerosis"

Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2013 by Le Bonheur Children's Hospital
Sponsor:
Collaborators:
Pfizer
University of Tennessee Health Science Center
Information provided by (Responsible Party):
James W. Wheless, Le Bonheur Children's Medical Center
ClinicalTrials.gov Identifier:
NCT01853423
First received: April 12, 2013
Last updated: November 7, 2013
Last verified: November 2013
  Purpose

The objective of this study is to evaluate the safety and efficacy of a 0.1% formulation of rapamune cream in children with Tuberous Sclerosis Complex (TSC), ages 3 years and older, who have facial angiofibromas that would benefit from treatment.


Condition Intervention Phase
Facial Angiofibroma
Drug: Rapamune
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream

Resource links provided by NLM:


Further study details as provided by Le Bonheur Children's Hospital:

Primary Outcome Measures:
  • Reduction of facial angiofibroma with use of rapamune facial skin cream [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    1. Tolerability: Number of participants with adverse events
    2. Efficacy: Skin assessment to measure improvement of facial angiofibromas
    3. Safety: Rapamune levels (serum)


Estimated Enrollment: 15
Study Start Date: October 2013
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rapamune
Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
Drug: Rapamune
Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
Other Name: Sirolimus

Detailed Description:

This is an open label, prospective single center study. Patients that are seen in our regional Tuberous Sclerosis Complex Clinic and have facial angiofibromas that would benefit from this cream and who wish to be involved in this study would be enrolled. We anticipate enrolling 12-15 patients the first year. Patients will have pictures of their facial angiofibromas taken immediately prior to entry into the study. They will then be prescribed 0.1% rapamune topical formulation to apply twice daily to their skin for the first two weeks and then once daily. If level is above 0, will re-check serum lipids, cbc, and repeat levels every three-four months and monitor the patient for symptoms. Patients will return at one month and three months to obtain serum rapamune levels along with pictures, then they will be seen intermittently throughout the first year with photographs of their face taken at the one month visit, 3 month visit, six month visit and twelve month visit. We will ask the parents about any side effects from the medication during the entire time patients are using the topical rapamune. We will monitor the facial lesions as well. We will assess for skin sensitivity, pain, erythema, or pruritus. If skin irritation results from the drug, then we will stop use of the drug. Parents will sign an informed consent allowing their child's picture to be taken and allowing us to summarize the data for publication at the end of this study.

This study will be the first study using a consistent formulation to make a 0.1% rapamune cream, and this will be performed under the direction of myself and Dr. Almoazen in the University of Tennessee Health Science Center(UTHSC) College of Pharmacy compounding laboratory. Only patients who are thought to be reliable for the follow up visits and to use the cream appropriately will be enrolled in the study. This study meets the FDA criteria for an Investigational New Drug(IND) exemption.

The adverse events noted in the package insert for rapamune cream are all based on systemic administration of the medication, primarily to adults with other diseases. In our clinical experience, with topical use there is no absorption and we have not noted any side effects.

  Eligibility

Ages Eligible for Study:   3 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient or his / her legally authorize representative (LAR) must sign and date the approved informed consent prior to study participation or initiation of study procedures. If appropriate, the patient will give written or verbal consent. Surrogate consent will be obtained utilizing the "legally authorized representative (LAR)". The LAR must be an adult who has exhibited special care and concern for the subject, who is familiar with the subject's personal values, who is reasonably available, and who is willing to serve. No person who is identified as a protective order or other court order that directs that person to avoid contact with the subject shall be eligible to serve as the subject's LAR. Identification of LAR should normally be made using the following order of descending preference: Conservator, guardian, attorney in fact, subject's spouse (unless legally separated), the subject's adult child, the subject's parent, the subject's adult sibling, any other adult relative of the subject, or other adult who is familiar with the patient's personal values, who is reasonably available, and who is willing to serve.

    1. Patient must have a diagnosis of Tuberous Sclerosis Complex.
    2. Female or male patients over the age of 3 years.
    3. Female subjects of child bearing potential must not be pregnant and must undergo a pregnancy test, and must agree to use appropriate contraceptive methods

      Exclusion Criteria:

  • Patients will be excluded from entry into the study if any of the following are true:

    1. Patient has a history of drug allergy to rapamune.
    2. Patient is pregnant or lactating.
    3. Subject is receiving therapy with Rapamycin.
    4. Subject is receiving any form of immunosuppression or has previously experienced immune dysfunction.
    5. Subject is currently participating in or has participated within the Last 30 days in a clinical trial involving an investigative drug.
    6. Subject has other dermatologic conditions that would preclude or prevent adequate assessment of changes to their facial angiofibromas.
    7. Subject has had laser surgery, cryotherapy, or other dermatologic treatment to their facial angiofibromas within the previous 6 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01853423

Contacts
Contact: Tracee Ridley, MSN, RN 901-287-5338 tracee.ridley@lebonheur.org
Contact: Catherine Horobetz, BSN, RN 901-287-5330 Catherine.Horobetz@mlh.org

Locations
United States, Tennessee
LeBonheur Children's Hospital Recruiting
Memphis, Tennessee, United States, 38103
Contact: Tracee Ridley, MSN, RN, CCRC    901-287-5338    tracee.ridley@lebonheur.org   
Contact: Catherine Horobetz, BSN, RN    901-287-5330    Catherine.Horobetz@mlh.org   
Principal Investigator: James W Wheless, MD         
Sponsors and Collaborators
Le Bonheur Children's Hospital
Pfizer
University of Tennessee Health Science Center
Investigators
Principal Investigator: James W Wheless, MD LeBonheur Children's Hospital- Neuroscience Institute
  More Information

Additional Information:
No publications provided

Responsible Party: James W. Wheless, Medical Doctor, Le Bonheur Children's Medical Center
ClinicalTrials.gov Identifier: NCT01853423     History of Changes
Other Study ID Numbers: UTHSC TSC01, 12-2008
Study First Received: April 12, 2013
Last Updated: November 7, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Le Bonheur Children's Hospital:
Rapamune
Topical
Pediatric
Safety
Efficiency
Angiofibroma
Skin Cream

Additional relevant MeSH terms:
Tuberous Sclerosis
Facies
Sclerosis
Angiofibroma
Disease Attributes
Pathologic Processes
Hamartoma
Neoplasms
Neoplasms, Multiple Primary
Neoplastic Syndromes, Hereditary
Malformations of Cortical Development
Nervous System Malformations
Nervous System Diseases
Neurocutaneous Syndromes
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Congenital Abnormalities
Genetic Diseases, Inborn
Neoplasms, Vascular Tissue
Neoplasms by Histologic Type
Sirolimus
Everolimus
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents

ClinicalTrials.gov processed this record on August 19, 2014